Mixed Pain (Nociceptive Pain/Neuropathic Pain) is an indication for drug development with over 270 pipeline drugs currently active. According to GlobalData, preregistered drugs for Mixed Pain (Nociceptive Pain/Neuropathic Pain) have a 69.57% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Mixed Pain (Nociceptive Pain/Neuropathic Pain) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mixed Pain (Nociceptive Pain/Neuropathic Pain) overview
Mixed pain involves a combination of nociceptive and neuropathic components, presenting a complex and challenging experience. Nociceptive pain originates from tissue damage, inflammation, or injury, activating pain receptors. Neuropathic pain results from nerve dysfunction, often described as burning, tingling, or shooting sensations. Conditions like diabetic neuropathy or post-surgical pain can exhibit this dual nature. Diagnosis requires a thorough clinical assessment. Treatment involves a multimodal approach, addressing both nociceptive and neuropathic aspects. Medications, physical therapy, and interventions targeting the underlying causes aim to provide comprehensive relief and improve the individual’s overall pain management and quality of life.
For a complete picture of PTSR and LoA scores for drugs in Mixed Pain (Nociceptive Pain/Neuropathic Pain), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
